Invitrogen Promotes Mark Gardner to Chief Marketing Officer; Process E

    Business Editors/Health/Medical Writers
    BIOWIRE2K

    CARLSBAD, Calif.--(BUSINESS WIRE)--May 3, 2005--Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today promoted Mark Gardner to Chief Marketing Officer for the company. In his new role, Gardner will lead the company's efforts in all areas of marketing, focusing on increasing the company's product vitality and new product sales, added support in "go-to-market" functions and expanding the reach of the Invitrogen brand throughout the industry.
    "One of our highest areas of focus is accelerating our organic growth rate through sales of new products," said Gregory T. Lucier, Invitrogen's Chairman and CEO. "In order to achieve success in this area, we need to reinvigorate the marketing supremacy Invitrogen has asserted over its history in the life sciences industry. Mark Gardner's expertise in driving effective and efficient processes will enable the powerful, consistent message about Invitrogen's superior technologies to resonate clearly with our customers."
    Gardner has served Invitrogen in several roles since 2003, including Vice President of Process Improvement, where he introduced concepts such as Six Sigma and LEAN to the company. Most recently, he served as Vice President of Commercial Marketing, where he established a global council to leverage opportunities across the spectrum of marketing channels for the company's product portfolio. He first came to Invitrogen after a series of highly successful six sigma and acquisition integration projects at General Electric Medical Systems, Information Technologies division. Prior to GE, Gardner was a McKinsey & Company consultant, where he focused on creating marketing solutions for a range of clients, and a lieutenant commander and pilot in the United States Navy. Gardner holds a bachelor of science degree from the United States Naval Academy, a masters degree in international relations from Georgetown University and an MBA from the Wharton School of Business at the University of Pennsylvania.
    "In the future of life science, the market is going to pick who succeeds," said Gardner. "Invitrogen is committed to winning in the marketplace by marketing and delivering products and services that enhance customer productivity across the entire spectrum of research, drug discovery, and production. My background in both commercial and process improvement roles gives me a unique understanding of how to deliver on this quest."

    About Invitrogen

    Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California and conducts business in more than 70 countries around the world. The company globally employs approximately 4,500 scientists and other professionals and had revenues of more than $1 billion in 2004. For more information, visit www.invitrogen.com.

    Safe Harbor Statement

    Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to: 1) Gardner's expertise will enable customers to better understand Invitrogen's technologies and initiatives; 2) Gardner's new position will enable him to grow Invitrogen's organic technologies and expand Invitrogen's brand in the life science industry. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks: a) Gardner's role may not result in better interaction with customers or increased sales; and b) Gardner may vary marketing and brand strategies; as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.

--30--SW/la*

CONTACT: Invitrogen Corporation Greg Geissman, 760-476-7032

KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICAL BIOTECHNOLOGY MANAGEMENT CHANGES SOURCE: Invitrogen Corporation

Copyright Business Wire 2005